This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rabbani, F. Articles by Bosl, G. J. Search for Related Content PubMed PubMed Citation Articles by Rabbani, F. Articles by Bosl, G. J. Social Bookmarking                            What's this?

Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse

From the Departments of Urology and Pathology and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Joel Sheinfeld, MD, Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room C-1076, New York, NY 10021; email: sheinfej{at}mskcc.org

PURPOSE: To determine the incidence, pattern, and predictive factors for relapse in patients with low-volume nodal metastases (stage pN1) at retroperitoneal lymphadenectomy (RPLND) and identify who may benefit from chemotherapy in the adjuvant or primary setting.

PATIENTS AND METHODS: Fifty-four patients with testicular nonseminomatous germ cell tumor had low-volume retroperitoneal metastases (pathologic stage pN1, 1997 tumor-node-metastasis classification) resected at RPLND, 50 of whom were managed expectantly without adjuvant chemotherapy. The dissection was bilateral in 12 and was a modified template in 38 patients. Retroperitoneal metastases were limited to microscopic nodal involvement in 14 patients. Follow-up ranged from 1 to 106 months (median, 31.4 months).

RESULTS: Eleven patients (22%) suffered a relapse at a median follow-up of 1.8 months (range, 0.6 to 28 months). The most frequent form of recurrence was marker elevation in nine (18%) patients. Persistent marker elevation after orchiectomy and before retroperitoneal lymphadenectomy was a significant independent predictor of relapse (relative risk, 8.0; 95% confidence interval, 2.3 to 27.8; P = .001). Four of five (80%) patients with elevated markers (alpha-fetoprotein alone in three, alpha-fetoprotein and beta human chorionic gonadotropin in one) suffered a relapse, compared with seven of 45 (15.6%) patients with normal markers.

CONCLUSION: Clinical stage I and IIA patients with normal markers who have low-volume nodal metastases have a low incidence of relapse and can be managed by observation only if compliance can be assured. In contrast, patients with elevated markers before retroperitoneal lymphadenectomy have a high rate of relapse and should be considered for primary chemotherapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. J. Guzzo and M. E. Allaf Laparoscopic retroperitoneal lymph node dissection for stage I and II nonseminomatous germ-cell tumors Therapeutic Advances in Urology, June 1, 2009; 1(2): 107 - 114. [Abstract] [PDF]

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				B. S. Carver, A. M. Serio, D. Bajorin, R. J. Motzer, J. Stasi, G. J. Bosl, A. J. Vickers, and J. Sheinfeld Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors J. Clin. Oncol., December 10, 2007; 25(35): 5603 - 5608. [Abstract] [Full Text] [PDF]

				J. Oldenburg, J. M. Martin, and S. D. Fossa Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis J. Clin. Oncol., December 10, 2006; 24(35): 5503 - 5511. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, G. J. Bosl, R. J. Motzer, M. W. Kattan, J. Stasi, D. F. Bajorin, and J. Sheinfeld Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome J. Clin. Oncol., April 20, 2005; 23(12): 2781 - 2788. [Abstract] [Full Text] [PDF]